Extended	B:C1707968
Release	I:C1707968
Guanfacine	O
in	O
Pediatric	O
Anxiety	O
Disorders	I:C0003469
:	O
A	O
Pilot	O
,	O
Randomized	O
,	O
Placebo	O
-	I:C1706408
Controlled	I:C1706408
Trial	O
.	O

Extended	O
Release	I:C1707968
Guanfacine	B:C0079466
in	O
Pediatric	O
Anxiety	O
Disorders	I:C0003469
:	O
A	O
Pilot	O
,	O
Randomized	O
,	O
Placebo	O
-	I:C1706408
Controlled	I:C1706408
Trial	O
.	O

Extended	O
Release	I:C1707968
Guanfacine	O
in	O
Pediatric	O
Anxiety	B:C0003469
Disorders	I:C0003469
:	O
A	O
Pilot	O
,	O
Randomized	O
,	O
Placebo	O
-	I:C1706408
Controlled	I:C1706408
Trial	O
.	O

Extended	O
Release	I:C1707968
Guanfacine	O
in	O
Pediatric	O
Anxiety	O
Disorders	I:C0003469
:	O
A	O
Pilot	B:C0031928
,	O
Randomized	O
,	O
Placebo	O
-	I:C1706408
Controlled	I:C1706408
Trial	O
.	O

Extended	O
Release	I:C1707968
Guanfacine	O
in	O
Pediatric	O
Anxiety	O
Disorders	I:C0003469
:	O
A	O
Pilot	O
,	O
Randomized	B:C0206034
,	O
Placebo	O
-	I:C1706408
Controlled	I:C1706408
Trial	O
.	O

Extended	O
Release	I:C1707968
Guanfacine	O
in	O
Pediatric	O
Anxiety	O
Disorders	I:C0003469
:	O
A	O
Pilot	O
,	O
Randomized	O
,	O
Placebo	B:C1706408
-	I:C1706408
Controlled	I:C1706408
Trial	O
.	O

Extended	O
Release	I:C1707968
Guanfacine	O
in	O
Pediatric	O
Anxiety	O
Disorders	I:C0003469
:	O
A	O
Pilot	O
,	O
Randomized	O
,	O
Placebo	O
-	I:C1706408
Controlled	I:C1706408
Trial	B:C0008976
.	O

This	O
is	O
a	O
feasibility	B:C0015730
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	B:C0220825
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	B:C3274448
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	B:C3179404
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	B:C2267005
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	B:C0079466
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	B:C1707968
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	B:C0270549
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	B:C0270549
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	B:C0003477
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	B:C0003477
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	O
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

This	O
is	O
a	O
feasibility	O
study	I:C0015730
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	I:C3179404
of	O
the	O
α2	O
agonist	I:C2267005
guanfacine	O
extended	O
-	I:C1707968
release	I:C1707968
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
(	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
)	O
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
(	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
)	O
,	O
or	O
social	B:C0031572
phobia	I:C0031572
/	O
social	O
anxiety	O
disorder	O
.	O

Youth	O
aged	O
6	O
-	O
17	O
years	O
with	O
a	O
primary	O
diagnosis	B:C0011900
of	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
were	O
treated	O
with	I:C0332293
flexibly	O
dosed	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
(	O
1	O
-	O
6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

Youth	O
aged	O
6	O
-	O
17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
generalized	B:C0270549
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
were	O
treated	O
with	I:C0332293
flexibly	O
dosed	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
(	O
1	O
-	O
6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

Youth	O
aged	O
6	O
-	O
17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	B:C0003477
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
were	O
treated	O
with	I:C0332293
flexibly	O
dosed	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
(	O
1	O
-	O
6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

Youth	O
aged	O
6	O
-	O
17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
were	O
treated	B:C0332293
with	I:C0332293
flexibly	O
dosed	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
(	O
1	O
-	O
6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

Youth	O
aged	O
6	O
-	O
17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
were	O
treated	O
with	I:C0332293
flexibly	O
dosed	O
guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
(	O
1	O
-	O
6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

Youth	O
aged	O
6	O
-	O
17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
were	O
treated	O
with	I:C0332293
flexibly	O
dosed	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
(	O
1	O
-	O
6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	B:C1696465
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	B:C3274448
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	B:C0003469
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	B:C0936012
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	B:C0087111
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	B:C0877248
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	B:C0877248
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	B:C0424000
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	B:C0518766
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	B:C0180580
/	O
laboratory	O
parameters	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
in	O
youth	O
with	O
anxiety	O
disorders	I:C0003469
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	I:C0877248
(	O
TEAEs	I:C0877248
)	I:C0877248
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	I:C0424000
and	O
behaviors	O
,	O
vital	O
signs	I:C0518766
,	O
and	O
electrocardiographic	O
/	O
laboratory	B:C0022877
parameters	O
.	O

Exploratory	O
efficacy	O
measures	O
included	O
dimensional	O
anxiety	B:C4050613
scales	I:C4050613
(	O
Pediatric	O
Anxiety	O
Rating	O
Scale	O
[	O
PARS	O
]	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
[	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
]	O
)	O
,	O
as	O
well	O
as	O
the	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
(	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
)	O
scale	O
.	O

Exploratory	O
efficacy	O
measures	O
included	O
dimensional	O
anxiety	O
scales	I:C4050613
(	O
Pediatric	O
Anxiety	O
Rating	O
Scale	O
[	O
PARS	O
]	O
and	O
Screen	B:C0681906
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
[	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
]	O
)	O
,	O
as	O
well	O
as	O
the	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
(	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
)	O
scale	O
.	O

Exploratory	O
efficacy	O
measures	O
included	O
dimensional	O
anxiety	O
scales	I:C4050613
(	O
Pediatric	O
Anxiety	O
Rating	O
Scale	O
[	O
PARS	O
]	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
[	O
Screen	B:C0681906
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
]	O
)	O
,	O
as	O
well	O
as	O
the	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
(	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
)	O
scale	O
.	O

Exploratory	O
efficacy	O
measures	O
included	O
dimensional	O
anxiety	O
scales	I:C4050613
(	O
Pediatric	O
Anxiety	O
Rating	O
Scale	O
[	O
PARS	O
]	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
[	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
]	O
)	O
,	O
as	O
well	O
as	O
the	O
Clinical	B:C3639708
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
(	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
)	O
scale	O
.	O

Exploratory	O
efficacy	O
measures	O
included	O
dimensional	O
anxiety	O
scales	I:C4050613
(	O
Pediatric	O
Anxiety	O
Rating	O
Scale	O
[	O
PARS	O
]	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
[	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
]	O
)	O
,	O
as	O
well	O
as	O
the	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
(	O
Clinical	B:C3639708
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
)	O
scale	O
.	O

As	O
this	O
was	O
an	O
exploratory	B:C1515369
study	I:C1515369
,	O
no	O
inferential	O
statistical	O
analyses	O
were	O
performed	O
.	O

guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
was	O
safe	O
and	O
well	O
tolerated	O
.	O

guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
was	O
safe	O
and	O
well	O
tolerated	B:C0013220
.	O

Treatment	B:C0087111
-	O
related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	O
rate	I:C0018810
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	O
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	O
blood	I:C0871470
pressure	I:C0871470
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
2.3	O
±	O
11	O
mm	O

Treatment	O
-	O
related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	B:C0018810
rate	I:C0018810
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	O
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	O
blood	I:C0871470
pressure	I:C0871470
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
2.3	O
±	O
11	O
mm	O

Treatment	O
-	O
related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	O
rate	I:C0018810
(	O
guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	O
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	O
blood	I:C0871470
pressure	I:C0871470
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
2.3	O
±	O
11	O
mm	O

Treatment	O
-	O
related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	O
rate	I:C0018810
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	B:C1696465
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	O
blood	I:C0871470
pressure	I:C0871470
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
2.3	O
±	O
11	O
mm	O

Treatment	O
-	O
related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	O
rate	I:C0018810
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	O
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	B:C0871470
blood	I:C0871470
pressure	I:C0871470
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
2.3	O
±	O
11	O
mm	O

Treatment	O
-	O
related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	O
rate	I:C0018810
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	O
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	O
blood	I:C0871470
pressure	I:C0871470
(	O
guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
2.3	O
±	O
11	O
mm	O

Hg	O
decrease	O
;	O
placebo	B:C1696465
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	O
blood	I:C0428883
pressure	I:C0428883
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	O
groups	O
.	O

Hg	O
decrease	O
;	O
placebo	O
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	B:C0428883
blood	I:C0428883
pressure	I:C0428883
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	O
groups	O
.	O

Hg	O
decrease	O
;	O
placebo	O
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	O
blood	I:C0428883
pressure	I:C0428883
(	O
guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	O
groups	O
.	O

Hg	O
decrease	O
;	O
placebo	O
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	O
blood	I:C0428883
pressure	I:C0428883
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	B:C1696465
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	O
groups	O
.	O

Hg	O
decrease	O
;	O
placebo	O
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	O
blood	I:C0428883
pressure	I:C0428883
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	B:C0087111
groups	O
.	O

Hg	O
decrease	O
;	O
placebo	O
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	O
blood	I:C0428883
pressure	I:C0428883
(	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	O
groups	B:C1257890
.	O

treatment	B:C0877248
-	I:C0877248
emergent	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
headache	O
,	O
somnolence	O
/	O
fatigue	O
,	O
abdominal	O
pain	I:C0000737
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
.	O

treatment	O
-	I:C0877248
emergent	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
headache	B:C0018681
,	O
somnolence	O
/	O
fatigue	O
,	O
abdominal	O
pain	I:C0000737
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
.	O

treatment	O
-	I:C0877248
emergent	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
headache	O
,	O
somnolence	B:C2830004
/	O
fatigue	O
,	O
abdominal	O
pain	I:C0000737
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
.	O

treatment	O
-	I:C0877248
emergent	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
headache	O
,	O
somnolence	O
/	O
fatigue	B:C0015672
,	O
abdominal	O
pain	I:C0000737
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
.	O

treatment	O
-	I:C0877248
emergent	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
headache	O
,	O
somnolence	O
/	O
fatigue	O
,	O
abdominal	B:C0000737
pain	I:C0000737
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
.	O

treatment	O
-	I:C0877248
emergent	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
headache	O
,	O
somnolence	O
/	O
fatigue	O
,	O
abdominal	O
pain	I:C0000737
,	O
and	O
dizziness	B:C0012833
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
.	O

treatment	O
-	I:C0877248
emergent	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
headache	O
,	O
somnolence	O
/	O
fatigue	O
,	O
abdominal	O
pain	I:C0000737
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	B:C0087111
groups	O
for	O
PARS	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
versus	O
placebo	O
demonstrated	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
scores	O
≤	O
2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	I:C0008961
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	B:C1257890
for	O
PARS	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
versus	O
placebo	O
demonstrated	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
scores	O
≤	O
2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	I:C0008961
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	O
for	O
PARS	O
and	O
Screen	B:C0681906
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
versus	O
placebo	O
demonstrated	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
scores	O
≤	O
2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	I:C0008961
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	O
for	O
PARS	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	B:C0080105
receiving	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
versus	O
placebo	O
demonstrated	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
scores	O
≤	O
2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	I:C0008961
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	O
for	O
PARS	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
versus	O
placebo	O
demonstrated	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
scores	O
≤	O
2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	I:C0008961
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	O
for	O
PARS	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
versus	O
placebo	B:C1696465
demonstrated	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
scores	O
≤	O
2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	I:C0008961
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	O
for	O
PARS	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
versus	O
placebo	O
demonstrated	O
Clinical	B:C3639708
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
scores	O
≤	O
2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	I:C0008961
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	O
for	O
PARS	O
and	O
Screen	O
for	I:C0681906
Child	I:C0681906
Anxiety	I:C0681906
Related	I:C0681906
Emotional	I:C0681906
Disorders	I:C0681906
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
versus	O
placebo	O
demonstrated	O
Clinical	O
Global	I:C3639708
Impression	I:C3639708
-	I:C3639708
Improvement	I:C3639708
scores	O
≤	O
2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	B:C0008961
investigator	I:C0008961
.	O

guanfacine	B:C1707968
extended	I:C1707968
-	I:C1707968
release	I:C1707968
was	O
well	O
tolerated	O
in	O
pediatric	O
subjects	I:C0080105
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
.	O

guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
was	O
well	O
tolerated	B:C0013220
in	O
pediatric	O
subjects	I:C0080105
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
.	O

guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
was	O
well	O
tolerated	O
in	O
pediatric	B:C0080105
subjects	I:C0080105
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
.	O

guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
was	O
well	O
tolerated	O
in	O
pediatric	O
subjects	I:C0080105
with	O
generalized	B:C0270549
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	O
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
.	O

guanfacine	O
extended	I:C1707968
-	I:C1707968
release	I:C1707968
was	O
well	O
tolerated	O
in	O
pediatric	O
subjects	I:C0080105
with	O
generalized	O
anxiety	I:C0270549
disorder	I:C0270549
,	O
separation	B:C0003477
anxiety	I:C0003477
disorder	I:C0003477
,	O
and	O
/	O
or	O
social	O
anxiety	O
disorder	O
.	O

